

What is Claimed is:

1. An oligonucleotide comprising at least 18 nucleotides, wherein the sequence is complementary to an mRNA encoding human integrin-linked kinase.

2. The oligonucleotide according to Claim 1, wherein said sequence is complementary to SEQ ID NO:1.

3. The oligonucleotide according to Claim 2, wherein said sequence is selected from the group consisting of SEQ NO:13 to SEQ ID NO:109.

4. The oligonucleotide according to Claim 3; and a pharmaceutically acceptable carrier.

5. A method of inhibiting expression of integrin linked kinase, the method comprising:

administering an oligonucleotide composition comprising an oligonucleotide comprising at least 18 nucleotides, wherein the sequence is complementary to an mRNA encoding human integrin linked kinase; and a pharmaceutically acceptable carrier.

6. The method according to Claim 5, wherein said sequence is complementary to SEQ ID NO:1.

7. The method according to Claim 6, wherein said sequence is selected from the group consisting of SEQ NO:13 to SEQ ID NO:109.